Literature DB >> 22052788

A stereodivergent strategy for the preparation of corynantheine and ipecac alkaloids, their epimers, and analogues: efficient total synthesis of (-)-dihydrocorynantheol, (-)-corynantheol, (-)-protoemetinol, (-)-corynantheal, (-)-protoemetine, and related natural and nonnatural compounds.

Wei Zhang1, Juho Bah, Andreas Wohlfarth, Johan Franzén.   

Abstract

Here we present a general and common catalytic asymmetric strategy for the total and formal synthesis of a broad number of optically active natural products from the corynantheine and ipecac alkaloid families, for example, indolo[2,3-a]- and benzo[a]quinolizidines. Construction of the core alkaloid skeletons with the correct absolute and relative stereochemistry relies on an enantioselective and diastereodivergent one-pot cascade sequence followed by an additional diastereodivergent reaction step. This allows for enantio- and diastereoselective synthesis of three out of four possible epimers of the quinolizidine alkaloids that begin from common and easily accessible starting materials by using a common synthetic route. Focus has been made on excluding protecting groups and limiting isolation and purification of synthetic intermediates. This methodology is applied in the total synthesis of the natural products (-)-dihydrocorynantheol, (-)-hirsutinol, (-)-corynantheol, (-)-protometinol, (-)-dihydrocorynantheal, (-)-corynantheal, (-)-protoemetine, (-)-(15S)-hydroxydihydrocorynantheol, and an array of their nonnatural epimers. The potential of this strategy is also demonstrated in the synthesis of biologically interesting natural product analogues not accessible through synthetic elaboration of alkaloid precursors available from nature, for example, thieno[3,2-a]quinolizidine derivatives. We also report the formal synthesis of (+)-dihydrocorynantheine, (-)-emetine, (-)-cephaeline, (-)-tubulosine, and (-)-deoxytubulosine.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052788     DOI: 10.1002/chem.201102012

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  8 in total

1.  Access to electron-rich arene-fused hexahydroquinolizinones through a gold-catalysis-initiated cascade process.

Authors:  Lianzhu Liu; Liming Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2012-06-12       Impact factor: 15.336

Review 2.  Recent advances of N-heterocyclic carbenes in the applications of constructing carbo- and heterocyclic frameworks with potential biological activity.

Authors:  Mei-Mei Li; Xiaozhen Chen; Yun Deng; Jun Lu
Journal:  RSC Adv       Date:  2021-11-26       Impact factor: 4.036

3.  A Concise, Enantioselective Approach for the Synthesis of Yohimbine Alkaloids.

Authors:  Eric R Miller; M Todd Hovey; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2020-01-17       Impact factor: 15.419

4.  Redox-Annulation of Cyclic Amines and β-Ketoaldehydes.

Authors:  Weijie Chen; Daniel Seidel
Journal:  Org Lett       Date:  2016-02-19       Impact factor: 6.005

Review 5.  The Chiral Pool in the Pictet-Spengler Reaction for the Synthesis of β-Carbolines.

Authors:  Renato Dalpozzo
Journal:  Molecules       Date:  2016-05-27       Impact factor: 4.411

6.  Design, Synthesis and Biological Evaluation of Highly Potent Simplified Archazolids.

Authors:  Solenne Rivière; Christin Vielmuth; Christiane Ennenbach; Aliaa Abdelrahman; Carina Lemke; Michael Gütschow; Christa E Müller; Dirk Menche
Journal:  ChemMedChem       Date:  2020-06-10       Impact factor: 3.466

7.  Asymmetric Redox-Annulation of Cyclic Amines.

Authors:  YoungKu Kang; Weijie Chen; Martin Breugst; Daniel Seidel
Journal:  J Org Chem       Date:  2015-10-02       Impact factor: 4.354

Review 8.  The Pictet-Spengler Reaction Updates Its Habits.

Authors:  Andrea Calcaterra; Laura Mangiardi; Giuliano Delle Monache; Deborah Quaglio; Silvia Balducci; Simone Berardozzi; Antonia Iazzetti; Roberta Franzini; Bruno Botta; Francesca Ghirga
Journal:  Molecules       Date:  2020-01-19       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.